A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis-Reference-Cited by-同舟云学术

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Published:2018-10-18 Issue:16 Volume:132 Page:1664-1674
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Masarova Lucia¹^ORCID,Verstovsek Srdan¹,Hidalgo-Lopez Juliana E.²,Pemmaraju Naveen¹,Bose Prithviraj¹,Estrov Zeev¹,Jabbour Elias J.¹,Ravandi-Kashani Farhad¹,Takahashi Koichi¹^ORCID,Cortes Jorge E.¹,Ning Jing³,Ohanian Maro¹,Alvarado Yesid¹,Zhou Lingsha¹,Pierce Sherry¹,Gergis Romany¹,Patel Keyur P.²,Luthra Rajyalakshmi²,Kadia Tapan M.¹,DiNardo Courtney D.¹,Borthakur Gautam¹,Bhalla Kapil¹,Garcia-Manero Guillermo¹,Bueso-Ramos Carlos E.²,Kantarjian Hagop M.¹,Daver Naval¹

Affiliation:

1. Department of Leukemia,

2. Department of Hematopathology, and

3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points The combination of RUX and AZA was safe with encouraging spleen response rates at 24 weeks and any time on study. RUX and AZA demonstrated marked improvements in bone marrow fibrosis at 24 months when compared with RUX alone.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/16/1664/1407094/blood846626.pdf

Reference32 articles.

1. New mutations and pathogenesis of myeloproliferative neoplasms;Vainchenker;Blood,2011

2. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

3. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

4. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial;Verstovsek;J Hematol Oncol,2017

5. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12

2. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations;Hematology;2023-12-08

3. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group;Clinical and Experimental Medicine;2023-09-25

4. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy;Leukemia & Lymphoma;2023-04-20

5. Pharmacotherapeutic advances for splenomegaly in myelofibrosis;Expert Opinion on Pharmacotherapy;2023-03-19